Yposkesi: Yposkesi begins construction of second bioproduction site
Backed by majority shareholder SK Pharmteco, Yposkesi is investing $71m in the 5,000 sqm facility. The construction is projected to create approximately 80 jobs by 2023
Read full article »
Yposkesi develops gene therapies for the treatment of AAV and lentiviral vector.
Read more